Collective member Deborah Gleeson highlights the barriers that intellectual property rights (IPRs) present in pandemic response.
Waiving intellectual property rights for COVID-19 health products and technologies is essential if we are to correct global health inequities and enable more equitable access, writes Collective member Deborah Gleeson.